762.20
+14.85
+(1.99%)
At close: 3:30:00 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
8,722,030
7,103,160
7,205,300
6,784,810
4,957,240
Cost of Revenue
3,997,330
3,204,030
3,442,940
2,936,520
1,753,230
Gross Profit
4,724,700
3,899,130
3,762,360
3,848,290
3,204,010
Operating Expense
2,008,100
1,873,840
1,822,220
1,573,260
1,340,100
Operating Income
2,716,600
2,025,290
1,940,140
2,275,030
1,863,910
Net Non Operating Interest Income Expense
27,210
26,570
-7,720
-28,620
-46,920
Pretax Income
3,130,330
2,200,950
2,166,110
2,432,300
1,846,570
Tax Provision
782,740
563,440
565,840
616,390
488,700
Net Income Common Stockholders
2,347,590
1,637,510
1,600,270
1,815,910
1,384,150
Diluted NI Available to Com Stockholders
2,347,590
1,637,510
1,600,270
1,815,910
1,384,150
Basic EPS
13.54
9.44
9.23
10.47
7.98
Diluted EPS
13.54
9.44
9.23
10.47
7.98
Basic Average Shares
173,361.84
173,465.43
173,465.43
173,465.43
173,465.43
Diluted Average Shares
173,361.84
173,465.43
173,465.43
173,465.43
173,465.43
Total Expenses
6,005,430
5,077,870
5,265,160
4,509,780
3,093,330
Net Income from Continuing & Discontinued Operation
2,347,590
1,637,510
1,600,270
1,815,910
1,384,150
Normalized Income
2,247,921.69
1,610,776.26
1,546,706.05
1,804,114.01
1,397,202.41
Interest Income
--
28,180
5,870
4,380
6,160
Interest Expense
950
1,590
13,570
32,800
46,890
Net Interest Income
27,210
26,570
-7,720
-28,620
-46,920
EBIT
3,131,280
2,202,540
2,179,680
2,465,100
1,893,460
EBITDA
3,336,890
2,483,450
2,430,420
2,682,710
2,090,080
Reconciled Cost of Revenue
3,997,330
3,204,030
3,442,940
2,936,520
1,753,230
Reconciled Depreciation
205,610
280,910
250,740
217,610
196,620
Net Income from Continuing Operation Net Minority Interest
2,347,590
1,637,510
1,600,270
1,815,910
1,384,150
Total Unusual Items Excluding Goodwill
132,900
35,470
72,140
15,800
-17,750
Total Unusual Items
132,900
35,470
72,140
15,800
-17,750
Normalized EBITDA
3,203,990
2,447,980
2,358,280
2,666,910
2,107,830
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
33,231.69
8,736.26
18,576.05
4,004.01
-4,697.59
3/31/2021 - 11/1/2023
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SMSLIFE.NS SMS Lifesciences India Limited
1,435.20
+13.02%
3BBLACKBIO.BO 3B BlackBio Dx Ltd
1,781.45
+0.45%
ONESOURCE.BO OneSource Specialty Pharma Limited
1,565.75
-0.69%
ZOTA.NS Zota Health Care Limited
883.40
+2.51%
ONESOURCE.NS ONESOURCE SPECL PHARMA L
1,564.60
-1.09%
BIOCON.BO Biocon Limited
331.20
+0.65%
PANACEABIO.NS Panacea Biotec Limited
522.95
+5.00%
SEER Seer, Inc.
1.9800
-5.71%
NUVL Nuvalent, Inc.
69.97
-1.14%
XERS Xeris Biopharma Holdings, Inc.
4.0800
-6.85%